Research programme: meningioma and neurilemmoma therapeutics - Vivace Therapeutics
Alternative Names: YAP-TEAD inhibitors - Vivace TherapeuticsLatest Information Update: 28 Jul 2024
At a glance
- Originator Vivace Therapeutics
- Developer Plymouth University; Vivace Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Meningioma; Neurilemmoma
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Meningioma in United Kingdom
- 28 Jul 2024 No recent reports of development identified for preclinical development in Meningioma in USA
- 28 Jul 2024 No recent reports of development identified for preclinical development in Neurilemmoma in United Kingdom